The Many Names of FDAAA - Take Your Pick
Executive Summary
Seven weeks after the Food and Drug Administration Amendments Act of 2007 was signed into law, some of the best minds in the world of pharmaceuticals remain vexed about one very important issue - what to call it.
You may also be interested in...
Where To Find Biosimilar User Fees In Alphabet Soup?
The industry is looking for a PDUFA, but could end up with a FDAAA as it searches for an acronym for the biosimilar user fee to join the lexicon of bureaucratic alphabet soup.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials